BS EN ISO 05840 — Cardiovascular Implants Cardiac Valve Prostheses Standard Series (General Requirements and Transcatheter-Implanted Valve Substitutes)

Cardiovascular Implants — Cardiac Valve Prostheses: General Requirements; Transcatheter-Implanted Heart Valve Substitutes

❤️ BS EN ISO 5840 is the British Standards Institution (BSI) implementation of the European Standard EN ISO 5840, corresponding to the international ISO 5840 series on cardiovascular implants, with the subject “cardiac valve prostheses”. The series has several parts; this batch covers two: Part 1 “general requirements” and Part 3 “heart valve substitutes implanted by transcatheter techniques”. In the UK it is prepared under Technical Committee CH/150/2 (Cardiovascular implants), and falls under ICS 11.040.40 (Implants for surgery). The series provides a unified basis for the safety, performance and clinical evaluation of artificial heart valves, and is a major technical support for market conformity of valve products under the Medical Device Regulation (MDR).

💡 A heart valve is an implanted device that “replaces the door of the heart”: its biocompatibility, haemodynamics and durability directly affect patient life. BS EN ISO 5840 refines valve evaluation from “can it be used” to “under what conditions it reaches what standard”, giving clinicians and regulators a common language.

1. Series Overview and Scope 📌

Cardiac valve prostheses replace native valves diseased by stenosis or regurgitation (aortic, mitral, etc.). The BS EN ISO 5840 series specifies requirements for design, materials, in-vitro testing, animal testing and clinical evaluation of cardiac valve prostheses, covering both surgical and transcatheter implant valves. Part 1 gives general requirements (terminology, classification, risk management, testing general principles), while Part 3 gives specific safety and performance requirements for valves implanted by transcatheter techniques (TAVI/TAVR, TMVR and other minimally invasive procedures).

⚠️ Transcatheter valves (e.g. TAVR) avoid open-chest surgery and are less invasive, but face specific risks: delivery systems, positioning and release, paravalvular leakage and long-term durability. Part 3 imposes more detailed device-performance and implantation-process requirements than for surgical valves.

2. Series Structure and Part List 📋

PartYearSubjectKey ContentApplicable Objects
BS EN ISO 5840-12015Cardiac valve prostheses — general requirementsTerminology, classification, risk management, materials, general test principlesAll cardiac valve prostheses
BS EN ISO 5840-32013Heart valve substitutes — transcatheter implantationDelivery/release system, implantation performance, paravalvular leakage, clinical evaluationTAVI/TAVR, TMVR and other transcatheter valves

Part 1 (2015) serves as the general top-level document providing a common basis for other parts; Part 3 (2013) gives specific requirements for transcatheter techniques, a rapidly developing minimally invasive procedure. Both parts were prepared under a mandate supporting EU Directive(s), including Annex ZA links to EU legislation.

3. Key Technical Requirements 🫀

3.1 General requirements (Part 1)

General requirements cover: valve classification (mechanical, tissue, transcatheter, etc.), design input (haemodynamic targets, valve size, materials), risk management (risk analysis per ISO 14971), in-vitro performance testing (transvalvular pressure gradient, effective orifice area, regurgitation fraction, valve opening/closing dynamics), durability (accelerated wear and pulsatile-flow fatigue), and animal/clinical evaluation.

3.2 Transcatheter valves (Part 3)

On top of the general requirements, Part 3 adds for transcatheter valves: manoeuvrability of the delivery system and catheter, compression/re-expansion performance of the valve in the delivery state, precise release and positioning, anchoring and sealing (prevention of paravalvular leakage), effects on perivalvular tissue and the conduction system (e.g. risk of atrioventricular block), and post-implant haemodynamic and long-term durability evaluation.

3.3 Materials and biocompatibility

Valve materials (metallic frames, polymers, biological tissue leaflets) must meet biocompatibility (per relevant ISO 10993 requirements), corrosion resistance, fatigue resistance and long-term stability; biological tissue should be appropriately processed and fixed to ensure structural integrity and anti-calcification performance.

3.4 Clinical and post-market evaluation

The standard emphasises the rigour of clinical evaluation and post-market surveillance, requiring haemodynamic, complication (thrombosis, embolism, bleeding, structural deterioration, paravalvular leakage, etc.) and patient follow-up data to be collected per clinical protocols, providing evidence for continuous improvement and regulatory decisions.

🚨 Valve failure is serious: structural deterioration, thromboembolism or paravalvular leakage can be life-threatening. In-vitro durability, haemodynamics and clinical follow-up are the “three pillars” of valve evaluation; failure of any one should preclude wide clinical use.

4. Cardiovascular Device Industry Application 🛠️

  • 🔍 Design and development: establish design input and risk-management documentation per Part 1 general requirements, providing the basis for in-vitro and animal testing.
  • 🔧 Type testing: perform in-vitro tests — transvalvular pressure gradient, effective orifice area, regurgitation, durability — per Parts 1/3, forming complete type-test reports.
  • 📊 Clinical evaluation: conduct clinical trials per the standard (e.g. pivotal clinical studies of transcatheter valves) and continue post-market follow-up.
  • 📋 Regulatory conformity: complete technical documentation, clinical evaluation and declarations of conformity per the Medical Device Regulation and EU Directive(s) to support CE certification and market access.

5. Frequently Asked Questions ❓

❓ Q: How do Parts 1 and 3 relate?
A: Part 1 is the general top-level requirement covering all cardiac valve prostheses; Part 3 targets transcatheter-implanted valves, adding specific requirements for delivery/release systems, anchoring and sealing, and implantation processes on top of the general requirements.
❓ Q: What are the main differences between transcatheter and surgical valves?
A: Transcatheter valves are implanted minimally invasively via catheter without open-chest surgery, but must solve delivery, precise release, anchoring and paravalvular leakage, with high long-term durability demands; surgical valves are implanted under direct vision, structurally simpler but more invasive.
❓ Q: Why accelerated durability testing?
A: A valve opens and closes about 100,000 times per day in vivo, so natural-life verification is impractical. Accelerated wear and pulsatile-flow fatigue tests accumulate millions of cycles in a short time to evaluate the fatigue life of leaflets and frames.
🔍 Q: How is paravalvular leakage evaluated?
A: After transcatheter valve implantation, the degree of paravalvular leakage should be assessed by imaging (e.g. echocardiography) and clinical follow-up; the standard requires it to be a key part of implantation performance and safety evaluation, compared with the surgical valve baseline.
🔒
正在加载下载地址,请稍候 10 秒

Leave a Reply

Your email address will not be published. Required fields are marked *